News
RVMD
36.77
+0.93%
0.34
Weekly Report: what happened at RVMD last week (0415-0419)?
Weekly Report · 1d ago
Noteworthy ETF Outflows: XBI, ALPN, RVMD, EXAS
NASDAQ · 4d ago
S&P 500 Futures Decline In Premarket Trading; Paramount Global, Revolution Medicines Lead
U.S. Stock markets set to open in two hours. Paramount Global was up 9.6% in pre-market trading. S&P 500 futures were down 0.33% in early trading. Stocks in Asia were down overnight. Bitcoin was up 1.95% to $64,785.
Barron‘s · 4d ago
Analysts Are Bullish on Top Healthcare Stocks: Intuitive Surgical (ISRG), Revolution Medicines (RVMD)
TipRanks · 4d ago
CORRECTED-U.S. RESEARCH ROUNDUP-Blackstone, Ellington Financial, Netflix
Blackstone, Ellington Financial, Netflix revise their ratings and price targets on several U.S. Companies. Deutsche Bank raises Abbvie Inc target price to $175 from $170, and cuts it to $140 from $145. Blackstone, ellington financial and Netflix also revise their targets on Friday.
Reuters · 4d ago
Weekly Report: what happened at RVMD last week (0408-0412)?
Weekly Report · 04/15 09:14
Top 10 stocks with upwards and downwards daily percentage change - Piper Sandler
Piper Sandler published the top 10 stocks with upwards and downwards daily percentage change as of Thursday. The S&P 500 (SP500) is vulnerable to a possible 5-10% pullback in upcoming weeks or months, analysts say. High-interest rates, inflation, and mediocre breadth are making the market vulnerable to pullback, Piper Sandler says.
Seeking Alpha · 04/12 15:34
Top 3 Health Care Stocks That May Collapse In Q2
Three stocks in the health care sector are overbought as of April 12, 2024. The RSI is a momentum indicator, which compares a stock's strength on days when prices go up to its strength when they go down. An asset is typically considered to be overb bought when the RSI value is above 70.
Benzinga · 04/12 12:34
Revolution Medicines Is Maintained at Outperform by Oppenheimer
Dow Jones · 04/12 12:23
Revolution Medicines Price Target Raised to $45.00/Share From $43.00 by Oppenheimer
Dow Jones · 04/12 12:23
Oppenheimer Maintains Outperform on Revolution Medicines, Raises Price Target to $45
Benzinga · 04/12 12:13
Oppenheimer Sticks to Their Buy Rating for Revolution Medicines (RVMD)
TipRanks · 04/12 11:47
Buy Rating Justified by Revolution Medicines’ Promising Preclinical Data in KRAS Mutant Cancer Therapies
TipRanks · 04/12 10:26
Revolution Medicines Receives Buy Rating Amid Promising Cancer Treatment Data and Expanded Market Opportunities
TipRanks · 04/12 10:26
Revolution Medicines Is Maintained at Buy by Needham
Dow Jones · 04/12 10:25
Revolution Medicines Price Target Raised to $46.00/Share From $36.00 by Needham
Dow Jones · 04/12 10:25
Needham Maintains Buy on Revolution Medicines, Raises Price Target to $46
Benzinga · 04/12 10:15
REVOLUTION MEDICINES INC <RVMD.O>: NEEDHAM RAISES TARGET PRICE TO $46 FROM $36
Reuters · 04/12 10:14
Revolution Medicines: An Expensive Shot At A Massive Market Opportunity
Revolution Medicines raised $238m via its 2020 IPO. The company is pioneering a unique approach to developing oncology drugs that target the RAS pathway. Its pipeline includes multiple drug candidates in clinical development, with promising early results in lung cancer and pancreatic cancer. Revolution's share price has grown by 30% since its IPO, bringing its market cap valuation to $6 billion.
Seeking Alpha · 04/12 08:14
REVOLUTION MEDICINES INC <RVMD.O>: OPPENHEIMER RAISES TARGET PRICE TO $45 FROM $43
Reuters · 04/12 04:18
More
Webull provides a variety of real-time RVMD stock news. You can receive the latest news about Revolution Medicines, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About RVMD
Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. Its RAS Companion Inhibitors are designed primarily for combination treatment strategies centered on its RAS(ON) Inhibitors. The Company’s RAS(ON) Inhibitors RMC-6236 RMC-6291 and RMC-9805 are in clinical development. RMC-6236, its RASMULTI(ON) inhibitor, is designed as a potent, oral, RAS-selective tri-complex inhibitor of multiple RAS(ON) variants, including cancer drivers.